증상성 신경인성 기립성 저혈압(SnOH) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Symptomatic Neurogenic Orthostatic Hypotension (SnOH) Market Outlook

Thelansis's "Symptomatic Neurogenic Orthostatic Hypotension (SnOH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Symptomatic Neurogenic Orthostatic Hypotension treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Symptomatic Neurogenic Orthostatic Hypotension (SnOH) Overview

Symptomatic Neurogenic Orthostatic Hypotension (SnOH) is a chronic and debilitating autonomic disorder characterized by a sustained drop in blood pressure upon standing (>=20 mmHg systolic or >=10 mmHg diastolic) due to impaired autonomic regulation. The condition arises from inadequate norepinephrine release from sympathetic neurons, resulting in failure to maintain vascular tone and cerebral perfusion during postural changes.

Clinically, SnOH presents with symptoms of cerebral hypoperfusion, including dizziness, lightheadedness, syncope, visual disturbances, and the characteristic "coat-hanger" neck and shoulder pain. It is commonly associated with neurodegenerative disorders such as Parkinson's Disease and other synucleinopathies, as well as peripheral autonomic neuropathies.

Management is complex and requires careful balancing of orthostatic symptom relief with the risk of exacerbating supine hypertension. The treatment paradigm follows a stepwise approach, beginning with non-pharmacological interventions (e.g., fluid and salt loading, compression garments), followed by pharmacological therapies such as fludrocortisone, midodrine, and droxidopa to improve vascular tone and circulating volume. Despite available therapies, symptom control remains suboptimal in many patients, and the condition significantly impacts quality of life and functional independence.

Key Highlights

• In France, moderate-to-severe SnOH cases are projected to increase from 11.0K in 2025 to 11.2K by 2035, reflecting minimal growth (0.2% CAGR) and a relatively stable patient population.
• Persistent symptoms and incomplete response to existing therapies highlight a continued unmet need for more effective and durable treatment options.
• Increasing awareness and improved diagnosis, particularly in aging populations and neurodegenerative conditions, are expected to support gradual patient identification.

Market Overview

• The Germany SnOH market is projected to grow from $9M in 2025 to $11M by 2035, reflecting modest growth in line with a small and stable patient population.
• Limited market expansion is primarily driven by:
• Incremental uptake of existing therapies (e.g., midodrine, droxidopa)
• Gradual improvements in diagnosis and treatment rates
• The market remains constrained by low disease awareness, underdiagnosis, and limited innovation in therapeutic options.
• Future growth will depend on improved disease recognition and the development of more effective therapies addressing both symptomatic control and underlying autonomic dysfunction.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• CuraSen Therapeutics
• Theravance Biopharma

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)